Biotech Values

[DewDiligence]

PKI sneaked in a Friday-evening 8-K filing stating that Kevin Hrusovsky (ex-CEO of Caliper Life Sciences, which PKI acquired in 2011: #msg-66915400) is leaving the company:

http://www.sec.gov/Archives/edgar/data/31791/000119312513214257/d536926d8k.htm

This suggests to me that PKI’s Caliper business, which Hrusovsky has continued to run since the 2011 buyout, is not doing as well as well as Hrusovsky expected. In light of PKI’s weak results in 1Q13, this is another reason to be somewhat bearish on PKI’s prospects.

On the other hand, PKI has buyout vig, and the sector in which it operates has been consolidating, as evidenced by the recent $16B TMO-LIFE deal (#msg-86836458). So there are reasons pro and con for continuing to hold.